Single-center, prospective, diagnostic trial. The primary objective of this study is to evaluate the sensitivity of 68Ga-PSMA PET /CT defined as the ratio between the number of 68Ga-PSMA PET /CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging.
The secondary objectives are:
* Sensitivity for different Prostatic Specific Antigen (PSA) values (ranges)
* Sensitivity for different lesion sites
* Treatment response assessment with a second PET
* False positives detection during Follow Up (FUP) (with other standard methods and eventually optional biopsy) for patient without any treatment
* safety 67 evaluable patients will be injected with 100-200 megabecquerel (MBq) 68Ga-PSMA intravenously
